Most questions about esketamine start the same way: "Wait, what is that?" That is not surprising. Our commissioned survey put the question to 443 Midwest adults, and 73 percent had not heard of Spravato, an esketamine nasal spray. Another 21 percent recognized the name only, and just 6 percent could describe it.
This FAQ is for people with employer-sponsored or individually purchased commercial insurance who are hearing about it for the first time and want straight answers. The survey data is final. Commercially insured respondents (173 of them) fared no better: 74 percent had never heard the name.
So what is it?
A prescription nasal spray, branded Spravato, whose FDA approval is for adults with treatment-resistant depression, the label for cases where at least two antidepressants, tried properly, have not brought enough relief. Most patients use it together with an antidepressant pill.
Why have I never heard of it?
It is rarely advertised to the public and is usually discussed only once standard treatment has not worked. People also do not search for it by name. Respondents who described what they would search for help wrote phrases like "therapist near me," with no drug names at all.
Is it the same as ketamine?
No. The two drugs are chemical relatives, but esketamine is its own FDA-approved product with its own safety rules. Ketamine used for depression, by IV infusion or in at-home telehealth programs, is off-label. At-home programs in particular involve much less supervision and are more often paid out of pocket.
How is it given?
Only in a certified healthcare setting. Staff watch while you spray it yourself, and you then remain for monitoring, since sleepiness, a detached feeling, and higher blood pressure can follow. Driving waits until the next day, after sleep, so arrange a ride home. The first weeks involve more frequent visits.
Does commercial insurance cover it?
Many commercial plans do, with conditions. The most common is prior authorization, which usually requires your doctor to document the antidepressants you have already tried. Plans differ, so the only reliable answer comes from your own insurer.
What should I ask my insurer?
- Is esketamine (Spravato) covered, and what are the criteria?
- Is prior authorization required?
- Does it bill to my medical coverage or my drug coverage?
- Which nearby certified centers are in my network?
- What does each visit cost me, and how does the deductible factor in?
How much does coverage matter to people?
More than anything else we asked about. When choosing a provider, 85 percent ranked insurance in their top two priorities. For 65 percent, coverage would be deciding or big in trying the treatment. Given a direct choice, a slim majority favored covered care with more steps, while 23 percent would rather pay out of pocket for a simpler process and 26 percent were unsure.
What does "medical benefit versus pharmacy benefit" mean for me?
Some treatment centers buy the medication and bill your insurer under your medical benefit. Others work with a specialty pharmacy that bills your pharmacy benefit. The route affects which deductible, copay, or coinsurance applies. Ask both the center and your insurer which way it will be billed.
Is there help with the cost?
Some commercially insured patients have gotten cost help through the manufacturer's patient support program. Eligibility varies, and manufacturer assistance generally does not apply to government insurance. Ask the treatment center, which often helps patients enroll. An FAQ page on Spravato also explains the approved treatment in plain language.
How do I find a treatment center?
Ask your doctor where they refer. Then use the manufacturer's online treatment center locator and cross-check each result against your insurer's directory. Call the center to confirm it accepts your plan for this specific treatment.
How far will I have to travel?
It depends on where you live. Certified centers are more common in larger metro areas. Because visits are frequent at first and you need a ride home, distance matters. Proximity weighed heavily in our data, landing in the top two for 43 percent.
Who should I talk to first?
Your doctor. That matches what 56 percent of our respondents said: primary care would be the first place they turned. And a doctor's recommendation was the single most persuasive factor, cited by 74 percent, far ahead of friends and family at 18 percent and advertising at 2 percent.
What if my doctor says it is not right for me?
Ask why, and ask what they would suggest instead. Other paths exist for depression that medication has not helped enough, including different medication strategies, psychotherapy, and TMS. Esketamine is also not appropriate for everyone. Some blood vessel conditions and other health factors rule it out.
And if the insurer says no?
Request the denial reason in writing, since many denials stem from missing documentation. Your doctor can submit more records or request a review call between doctors. Filing an internal appeal is another right you have, and many plans then allow an independent external review.
Will my employer know?
Your employer generally does not see the details of your medical claims; health privacy laws limit what your plan can share. If you need time off for treatment, you may choose to talk to HR about leave, but what you disclose is largely up to you. If you have concerns, ask HR how privacy is handled in your plan.
Is esketamine a cure?
No treatment can promise that. Esketamine is one option clinicians consider for treatment-resistant depression. How well it works varies by person, and a clinician will monitor your response.
What is the first step?
Make a list of each antidepressant you have taken, how much, and for roughly how long. Book an appointment specifically about your depression. Bring the list, and ask your doctor what comes next.
If you are thinking about suicide right now, do not wait for any of these steps. Text or call 988 instead. That line, the Suicide and Crisis Lifeline, charges nothing, stays private, has people on duty through the night, and lets veterans press 1.
Methodology
Data come from a questionnaire we placed on Pollfish's consumer panel. Prior to closing on June 23, 2026, it had gathered answers from 443 respondents, ages 18 to 64, in Kansas, Iowa, Ohio, Missouri, Illinois, Nebraska, Minnesota, Oklahoma, Wisconsin, and Indiana. Results here are whole-sample, apart from the commercial-insurance group noted above. All numbers reflect the panel's final validation. This survey was commissioned by the publisher, which paid for it. Plan details vary; this FAQ is not medical or insurance advice.